The clinical use of cytotoxic deoxynucleoside analogues is often limited by resistance mechanisms due to enzymatic deficiency, or high toxicity in nontumor tissues. To improve the use of these drugs, gene therapy approaches have been proposed and studied, associating clinically used deoxynucleoside analogues such as araC and gemcitabine and suicide genes or myeloprotective genes. In this review, we provide an update of recent results in this area, with particular emphasis on human deoxycytidine kinase, the deoxyribonucleoside kinase from Drosophila melanogaster, purine nucleoside phosphorylase from Escherichia coli, and human cytidine deaminase. Data from literature clearly show the feasibility of these systems, and clinical trials are warranted to conclude on their use in the treatment of cancer patients.
Introduction
Deoxynucleoside analogues are widely used in the treatment of hematological malignancies and solid tumors. A limiting factor in the use of these agents is the appearance of resistance or the presence of nonresponding cancer cells. 1 Several approaches are currently being developed to improve the antitumor activity of deoxynucleoside analogues, such as enzyme inhibitors, pronucleotides, pharmaceutical formulation and gene therapy. Thanks to the knowledge of the mechanisms of action and the major resistance mechanisms described for these molecules, several gene therapy strategies have been proposed. In this review, we will give an overview of currently available data concerning gene therapy strategies that can be associated with the clinically used deoxynucleoside analogues araC, gemcitabine, fludarabine, cladribine, clofarabine and troxacitabine (Table 1) . These approaches mainly consist in suicide gene therapy with deoxyribonucleoside kinases or Escherichia coli purine nucleoside phosphorylase (PNP), and myeloprotection with cytidine deaminase (CDA; Figure 1 ). Suicide gene therapy is based on the introduction of a drugmetabolizing gene into the cancer cells to specifically sensitize these to the cytotoxic effect of nucleoside analogues. An inactive prodrug administered systemically should therefore be nontoxic for normal cells while being specifically activated and cytotoxic in transfected tumor cells. Myeloprotective gene therapy is based on the introduction of a gene conferring resistance to chemotherapeutic agents, into normal blood stem cells. When these cells are reintroduced into the bone marrow before chemotherapy the hematological toxicity will be decreased because the gene product will inactivate the drug. Given the frequent and serious consequences of hematological toxicity of chemotherapeutic agents in general and nucleoside analogues in particular, this constitutes another approach to decrease lethal side effects and thereby allow clinicians to increase doses. This review will focus on those nucleoside compounds, which are toxic for mammalian cells. Systems involving herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir (GCV) or E. coli cytosine deaminase and 5-fluorocytosine will not be discussed and have been widely reported elsewhere.
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Human deoxycytidine kinase
The human deoxycytidine kinase (dCK) gene was cloned in 1991 by Chottiner et al. 5 The identified sequence encodes a 61 kDa phosphokinase consisting of two identical 30.5 kDa subunits. dCK is a pivotal enzyme involved in the salvage pathway of deoxyribonucleotide biosynthesis, which provides deoxyribonucleotides for DNA synthesis and repair. This enzyme phosphorylates the natural deoxyribonucleosides deoxycytidine (dC), deoxyadenosine (dA) and deoxyguanosine (dG), and also the nucleoside analogues araC, cladribine, fludarabine and gemcitabine. Phosphorylation of these compounds by dCK is essential for the compounds routinely used in cancer chemotherapy and is the rate-limiting step in their overall activation pathway.
To know whether the level of dCK activity in malignant cells is correlated with response to chemotherapy, Hapke and co-workers infected MCF-7 (breast carcinoma), HT-29 (colon carcinoma) and H1437 (small cell lung adenocarcinoma) tumor cell lines with a retroviral vector containing dCK. dCK activity was increased 1.7-, 2.3-, and 16-fold in MCF-7, HT-29 and H1437 cells, respectively. The three cell lines showed an increase in drug sensitivity to araC and CDA, showing for the first time a direct effect of dCK activity on drug sensitivity in cancer cell lines.
6 Table 1 Names and structures of clinically used cytotoxic nucleoside analogues Gene therapy and nucleoside analogues C Hébrard et al dCK has been largely used as a candidate for suicide gene therapy both in vitro and in vivo. Transduction of the dCK cDNA in human glioma cell line 9L resulted in marked sensitization to araC in vitro. 7 Similar results have been shown in human A549 lung carcinoma, murine NIH3T3 fibroblast and human SCC-25 squamous carcinoma cell lines. 8, 9 Sometimes, untransfected cells surrounding transfected cells are killed after incubation with the inactive prodrug. This is called bystander effect and is due to the transfer of toxic metabolites or proapoptic compounds from the cells expressing the transgene to the other cells. A minor bystander effect has been observed in the 9L cells overexpresssing dCK, because 50 or 70% of the total cell population was killed following araC exposure in vitro when untransduced 9L cells were mixed with 10 or 50% of 9L-dCK cells, respectively. The dCK overexpression in 9L cells also showed significant antitumor effects in vivo after establishment of intradermal and intracerebral gliomas in rats followed by araC treatment. 7 Increased expression of dCK cDNA in HT-29 xenografts resulted in an enhanced accumulation of gemcitabine triphosphate (dFdCTP) and prolonged elimination kinetics, and ultimately potentiated the in vivo tumor response to gemcitabine. 10 dCK transduction has been used in dCK-deficient cell lines to revert resistance. The araC-resistant rat leukemic cell line RO/1-A has been shown to have a typical dCKdeficient phenotype and cannot metabolize araC. These cells were transduced with dCK and a 12-fold increased phosphorylation efficiency for both dC and araC compared with parental cell line was observed, resulting in a fully restored sensitivity to araC. 11 dCK-deficient Chinese hamster ovary (CHO) cells reconstituted with dCK targeted to either the cytosol or the nucleus showed similar sensitivity to araC and gemcitabine indicating that the cellular localization of dCK has no impact on phosphorylation of these drugs. 12 However, a bystander effect occurred when nucleoside analogues were phosphorylated in the cytotosol but not when these compounds were phosphorylated in the mitochondria, indicating a decreased diffusion of active metabolites in this case. 13 In addition, hydroxyurea showed synergistic cytotoxicity with araC when dCK was expressed in the cytosol or in the nucleus of CHO cells, but not when dCK was expressed in the mitochondria. 14 dCK gene therapy has been used in combination with uridine monophosphate kinase (UMK). In this strategy, the kinases needed for the two first phosphorylation steps of gemcitabine are introduced in the cancer cells, facilitating the production of gemcitabine diphosphate and not only monophosphate. The pancreatic carcinoma PC1.0 cell line transduced with a fusion gene combining dCK and UMK showed sensitization to gemcitabine by reducing dramatically both in vitro cell viability and in vivo tumor volume. 15 Intracranial tumors derived from murine GI261, rat C6 and human U373 glioma cell lines showed recently enhanced cytotoxic and radiosensitizing effect of gemcitabine in vivo. 16 The cocrystallization of dCK in the presence of nucleosides and nucleoside analogues has provided information on the sites involved in substrate binding and enzyme activity. [17] [18] [19] However, the development of a triple mutant dCK (A100V/R104M/D133A) increased the phosphorylation efficiency toward dC but not toward araC or gemcitabine, suggesting it is not suitable for a suicide gene approach. 19 
Drosophila melanogaster deoxyribonucleoside kinase
Another kinase that has been largely studied as a potential suicide gene in combination with cytotoxic deoxynucleoside analogues is the unique deoxyribonucleoside kinase from Drosophila melanogaster (Dm-dNK), first purified and characterized by Munch-Pertersen and co-workers in 1998. 20 This monomeric enzyme of about 30 kDa shows broad substrate specificity, because it is able to phosphorylate all the natural pyrimidine and purine deoxyribonucleosides with high efficiency, as compared with the mammalian kinases. Indeed, the enzyme exhibits a catalytic rate that is 10-to 100-fold higher than that reported for the previously studied deoxyribonucleoside kinases. Its broad substrate specificity and high catalytic rate make Dm-dNK a unique member of the nucleoside kinase enzyme family. Moreover, this multisubstrate enzyme is also able to efficiently phosphorylate several antiviral and anticancer nucleoside analogues, such as araC, gemcitabine and AZT. 20, 21 All these properties make Dm-dNK an interesting candidate for suicide gene therapy in cancer. 
Gene therapy and nucleoside analogues C Hébrard et al
To evaluate Dm-dNK as a suicide gene, Zheng and coworkers transduced the human pancreatic adenocarcinoma cell line MIA PaCa-2 and a thymidine kinase-deficient osteosarcoma cell line with a replication-deficient retroviral vector coding the kinase. 22 They showed that DmdNK expressed in human cells retains enzymatic activity, because the transduced cells exhibited 35-100 higher level of dThd phosphorylation. Moreover, the cells that expressed Dm-dNK showed an increased sensitivity to several cytotoxic nucleoside analogues, that is, up to 213-fold for gemcitabine, 61-fold for araC and 409-fold for cladribine. Similar results were obtained with araC in HeLa cells. 23 It was further shown that the sensitizing effect of Dm-dNK on cytotoxicity of araT and bromovinyldeoxyuridine (BVDU), which is a selective HSV compound that is nontoxic in cells not expressing DmdNK, is not dependent on the subcellular localization of the enzyme. 24 In fact, active GFP-fused Dm-dNK expressed in the cytosol or in the nucleus mediated similar increases in sensitivity to cytotoxic compounds. The ribonucleotide reductase inhibitor hydroxyurea has been shown to enhance cell death in cells transduced with DmdNK and treated with BVDU. The IC 50 was 150-fold lower for Dm-dNK-expressing osteosarcoma cells incubated with BVDU in the presence of hydroxyurea than for cells incubated with BVDU alone. 25 Therefore, hydoxyurea could be used in association to increase the efficiency of the Dm-dNK/BVDU combination, in particular because untransfected cells are not sensitive to BVDU. Hydroxyurea would, however, induce additional side effects by action on normal cells as it is not dependent on the transgene. Zheng et al. also investigated whether the cells expressing Dm-dNK can induce cell death of untransduced cells. They observed this bystander effect in a thymidine kinase-deficient human osteosarcoma cell line after incubation with BVDU. 24, 25 This phenomenon, however, seems to be cell line dependent because it was not observed in MIA PaCa-2 cells.
Resistance to cytotoxic deoxynucleoside analogues observed in cell line models or in clinical samples is often due to dCK deficiency. To reverse gemcitabine resistance in the human uterine sarcoma cell line Messa 10K, we transiently transfected these cells with a Dm-dNKcontaining pcDNA3 vector. 26 Dm-dNK-transfected Messa 10K cells were only 3.83-fold less sensitive to gemcitabine than dCK-proficient Messa wild-type (wt) cells and showed a 6.16-fold decrease in IC 50 value as compared to Messa 10K cells. Messa 10K cell line is 26.4-fold less sensitive to the cytotoxic action of gemcitabine than the Messa wt cell line. This shows that Dm-dNK can be used to regain activity of deoxynucleoside analogues in dCK-deficient cells.
Suicide gene therapy has been employed in clinical trials of allogeneic stem cell transplantation, to permit modulation of alloreactivity after transplantation. [27] [28] [29] Two T-lymphoblastoid cell lines were transduced with Dm-dNK and showed an increase in sensitivity toward pyrimidine nucleoside analogues such as BVDU, but not to the antiherpetic nucleoside analogues GCV, acyclovir (ACV) and penciclovir (PCV). 30 Immuno-suppressed patients often suffer from herpes virus infections, and if GCV or ACV is used to treat these infections, the compounds will also be activated in the suicide genecarrying T cells if HSV-TK is used as the suicide gene. However, if, Dm-dNK is used as the donor T-cell suicide gene, only BVDU will affect these cells, whereas GCV, ACV or PCV will have no effect. It could therefore be an advantage to use Dm-dNK in donor T cells for bone marrow transplantation applications. Mutants of Dm-dNK have been developed and studied to obtain kinases with higher specificity or even better activity. The amino acids 28, 29, 52, 70, 81, 105 and 114 have been mutated, and mutants were shown to have different properties than wt Dm-dNK. 31, 32 Sites involved in the substrate specificity have also been identified, and cells expressing some mutants are specifically more sensitive to purine derivatives than the wt Dm-dNK. [33] [34] [35] Finally, hybrid enzymes of Dm-dNK and human thymidine kinase 2 were shown to have higher activity on thymidine derivatives than Dm-dNK or TK2, but lower activity on fludarabine or gemcitabine. 36 Escherichia coli purine nucleoside phosphorylase Human PNP, a homotrimeric enzyme with a total molecular weight of about 100 kDa, is specific for 6-oxopurine nucleosides and has poor activity on 6-aminopurine nucleosides. 37 In contrast, E. coli PNP is a homohexameric enzyme with a total molecular weight of about 150 kDa and catalyzes the reversible cleavage of purine nucleosides or 2 0 -deoxynucleosides to the corresponding free nucleobases and sugar-coupled phosphates. Differences in the active site allow E. coli PNP to accept purine nucleosides with 6-oxo, 6-amino and some nonstandard 6-substituents and to activate certain adenosine analogues such as 6-methyl-purine-2 0 -deoxyribonucleoside (MeP-dR) or fludarabine that are not substrates for the human enzyme. [38] [39] [40] Cleavage of these adenosine analogues by PNP results in the production of adenine compounds, which are highly toxic to dividing and nondividing cells by interfering with DNA, RNA and protein synthesis. 41 Such molecules are able to diffuse across cell membranes, resulting in potent bystander effects. 39, [42] [43] [44] Therefore, E. coli PNP in association with fludarabine seems to have all the required qualities to be used in suicide gene therapy in cancer.
The PNP/fludarabine suicide gene system has been compared with the well-described HSV-TK/GCV system in hepatocellular carcinoma (HCC) cells. Indeed, HSV-TK is the prototype suicide gene and several studies have shown that HCC cells expressing the HSV-TK gene become highly sensitive to the antiviral drug GCV. 45, 46 Human HCC cell lines HepG2, Hep3B and HuH-7 were transduced with PNP or HSV-TK gene and treated with fludarabine and GCV, respectively. 47 Expression of PNP highly sensitized HCC cells to fludarabine treatment. Expression of PNP in as few as 10% of HCC cells induced efficient killing of most bystander cells. HCC cells expressing HSV-TK treated with GCV showed a potent growth inhibition even though cell death was not complete. Moreover, the HSV-TK system exhibited a less pronounced bystander effect. Adenoviral delivery of PNP followed by fludarabine administration prevented subcutaneous and intrahepatic tumor formation in nude mice and was also effective for the treatment of established tumors. Thus, PNP/fludarabine seems to be a more efficient suicide gene system than HSV-TK/GCV in HCC cells.
To analyze the mechanisms involved in PNP/fludarabine-mediated cell death in human HCC cells in comparison with HSV-TK/GCV, the HepG2 and Hep3B HCC cell lines were transduced with PNP or HSV-TK and incubated with the prodrugs GCV or fludarabine. Transduction of PNP gene followed by treatment with nucleoside analogues has been studied in vivo on bladder tumors, pancreatic adenocarcinomas, gliomas, ovarian or prostate tumors and showed different levels of growth inhibition. 40, 44, [49] [50] [51] [52] [53] [54] [55] [56] To increase the effect obtained with this gene-therapy approach by using new genes and new drugs, a study based on crystallographic and computer modeling of E. coli PNP, was performed. The mutated protein (M64V) had a more than 100-fold increased enzymatic efficiency (kcat/Km) toward the nontoxic 9-(6-deoxy-a-L-talofuranosyl)-6-methylpurine as compared to the wt protein. 57 This result shows the possibility to develop new suicide gene/prodrug systems based on PNP.
A phase I clinical trial was initiated in 2008 (ClinicalTrials.gov identifier: NCT00625430). The aim of this study is to evaluate the safety and tolerability of the use of FP253, an ovine atadenovirus that expresses the E. coli PNP, and fludarabine in prostate cancer patients.
Myeloprotection with cytidine deaminase
As chemotherapy is often associated with important hematological toxicity, myeloprotective gene therapy has been proposed to allow the use of increased doses during cancer treatment. 58, 59 For this purpose, genes involved in the resistance to the drugs have been used as transgenes to protect myeloid stem cells.
CDA converts the cytidine analogues araC and gemcitabine into their inactive derivatives araU and dFdU. [60] [61] [62] The relevance of this inactivation for the activity of these compounds has been shown both on cell models and in vivo using in particular the CDA inhibitor 3,4,5,6-tetrahydrouridine (THU). [63] [64] [65] [66] Because of the high enzyme activity of CDA toward araC and gemcitabine in vitro and in vivo, this gene has been used to protect hematopoietic cells from the cytotoxic effect of these two drugs.
First it was shown that overexpression of CDA in a retroviral LXSN-vector in mouse fibroblasts NIH3T3 induced 4.5-fold and 2.1-fold increases in IC 50 of araC and gemcitabine, respectively. 67 In human acute lymphoblastic leukemia cells CCRF-CEM, the resistances observed were 2.1-fold and 2.4-fold. This result was confirmed by others, both on fibroblasts and mouse bone marrow with araC, gemcitabine and 5-aza-deoxycytidine. [68] [69] [70] [71] [72] It was also shown that the resistance was reversed by using THU. 70 In the next step, transduced hematopoietic cells were transplanted into the bone marrow of mice to show the production of CDA in blood and different tissues. 73 Human CDA activity was observed in these mice 11-13 months after transplantation, and cells from bone marrow and spleen were resistant to araC in an ex vivo experiment. In vitro selection of transduced cells to select cells with high CDA expression before transplantation was easily obtained with murine leukemic L1210 cells and, although less easily, in murine bone marrow cells. 72 The selection was further applied to human peripheral and cord blood progenitor cells with araC and gemcitabine. 74 Finally, in vivo myeloprotection has been observed in mice treated with araC or gemcitabine after transplantation of CDAtransduced murine bone marrow cells. 75 Nadir values of granulocytes and thrombocytes in araC-treated CDA overexpressing mice were fourfold and sixfold higher than in control mice whereas threefold differences were observed with gemcitabine.
A short form of CDA obtained from alternative splicing has been described. 76 However, this form is not active and is therefore not suitable for resistance-induced gene therapy. Studies on the activity of proteins encoded by different polymorphic variants have allowed the identification of some residues involved in the activity of the protein. First, two variants of the nonsynonymous polymorphism Lys27Glu have been shown to have different catalytic activity toward araC and gemcitabine. 77, 78 Second, CDA with a threonine in position 70 is less active toward araC than the protein with an alanine in this position. 79 Some indispensable residues have been identified by site-directed mutagenesis, such as amino acids 33 and 137 that seem to be implicated in the tetramerization of the protein. 80 A CDA with increased activity on araC or gemcitabine, and thereby particularly adapted for myeloprotective gene therapy, could be identified during further studies on variant proteins.
Troxacitabine, a cytidine analogue of the nonnatural L-series is not a substrate for CDA. 81 The cytotoxicity of troxacitabine is similar in CDA-overexpressing cells, indicating that this kind of gene therapy is not suited for this molecule. 82 It has also been shown that troxacitabine remains cytotoxic in leukemic cells resistant to araC due to increased CDA-expression. 83 An additional advantage of the CDA system, is the fact that increased expression of CDA sensitizes cells to the cytotoxic effect of the pyrimidine analogue and precursor of 5-fluorouracil capecitabine. 66 CDA has also been used in a combination system with a double mutant of dihydrofolate reductase (DHFR) and treatment with both araC and methotrexate. This combination is widely used in the treatment of nonHodgkin's lymphoma. Based on the fact that myelosuppression is the main toxicity of the two cytotoxic agents, a hematoprotective gene therapy strategy has been proposed. A double mutant of DHFR (Leu22Phe-Phe31Ser) was shown to induce high level of resistance to methotrexate in murine fibroblasts. 84 When a double mutant DHFR-CDA fusion gene was transfected into the same cells, a 10-to 12-fold resistance was observed for araC and a 500-to 1000-fold resistance to methotrexate. Resistance was also observed in mouse bone marrow cells, and transfected cells had a 3-to 6-fold increase in the enzymatic activities of DHFR and CDA. Introduction of the fusion gene in mice allowed an increase of araC and methotrexate doses, inducing a prolonged survival and better tumor response. 85 
New systems and perspectives
The gene suicide systems described here are the most extensively studied, and are associated with clinically used deoxynucleoside analogues. However, other systems have been proposed or are potentially developable in this setting. Another deaminase, the deoxycytidylate deaminase or DCTD, has been proposed as a candidate gene for myeloprotective gene therapy associated with araC treatment. However, results obtained after transfection of this gene in murine fibroblasts were not promising enough to continue this approach. 86 Other genes involved in resistance and the cellular response to cytotoxic deoxynucleoside analogues could be used for the protection of hematopoietic cells. In particular, increased expression of the large subunit of the ribonucleotide reductase, RRM1, has been shown to be implicated in the resistance to gemcitabine and this gene could therefore represent another gene therapy candidate. [87] [88] [89] High expression levels of the cytoplasmic 5 0 -nucleotidease II has also been correlated to decreased response to araCbased treatment. 90 However, direct proof of the involvement of this enzyme or other 5 0 -nucleotidases in the resistance to deoxynucleoside analogues is not yet available, but necessary to start investigations with these genes in gene therapy approaches.
Recently, deoxyribonucleoside kinases phosphorylating gemcitabine have been identified in different bacteria. 91, 92 These kinases, or eventually engineered forms of them, might be used as suicide genes in combination with gemcitabine to kill dCK-deficient cancer cells. Finally, a large amount of data exist on mutants of nucleoside transporters and their differential activity on deoxynucleoside analogue transport in cells. 1 These genes could eventually be used to sensitize transporter-deficient deoxynucleoside-resistant cancer cells. In fact, decreased nucleoside transporter expression has been shown to be correlated to decreased response to deoxynucleoside analogue-based treatment.
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Conclusive remarks
Resistance to anticancer drugs due to insufficient intracellular metabolism and formation of active metabolites is a major limitation in the care of cancer patients. In addition to the development of new molecules, an important amount of work is underway to improve the activity of already existing agents. In the field of deoxynucleoside analogues, gene therapy approaches based on suicide genes or myeloprotection has been largely developed, in particular during the last decade. Even though highly efficient suicide genes and prodrug systems, such as HSV-TK/GCV, exists, it is crucial to search for new combinations to improve therapeutic efficacy. Results from studies presented in this review are situated somewhere between early molecular descriptions and clinical studies. Before initiating evaluation on humans, studies on clinically pertinent animal models are required. This seems to present the next step in the development of gene therapy in association with cytotoxic nucleoside analogues. Taken individually, these approaches may constitute minor advances in the fight against cancer, but they could provide the knowledge needed for the effective treatment of cancer patients with deoxynucleoside analogues in association with gene therapy. 
